HRP20221385T1 - Makrociklički spoj i njegova uporaba - Google Patents
Makrociklički spoj i njegova uporaba Download PDFInfo
- Publication number
- HRP20221385T1 HRP20221385T1 HRP20221385TT HRP20221385T HRP20221385T1 HR P20221385 T1 HRP20221385 T1 HR P20221385T1 HR P20221385T T HRP20221385T T HR P20221385TT HR P20221385 T HRP20221385 T HR P20221385T HR P20221385 T1 HRP20221385 T1 HR P20221385T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- compound
- use according
- pharmaceutically acceptable
- her2
- Prior art date
Links
- 150000002678 macrocyclic compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 9
- 206010006187 Breast cancer Diseases 0.000 claims 6
- 208000026310 Breast neoplasm Diseases 0.000 claims 6
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 6
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000002313 intestinal cancer Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 230000009545 invasion Effects 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 201000003076 Angiosarcoma Diseases 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 208000001258 Hemangiosarcoma Diseases 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 101710132701 Protein L1 Proteins 0.000 claims 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims 1
- 201000011281 bladder sarcoma Diseases 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims 1
- 206010073373 small intestine adenocarcinoma Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 206010042863 synovial sarcoma Diseases 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000023747 urothelial carcinoma Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Claims (15)
1. Spoj sljedeće strukture:
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Farmaceutski pripravak naznačen time što sadrži spoj prema zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, u farmaceutski prihvatljivom nosaču.
3. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1 za uporabu u inhibiciji rasta tumora ili raka naznačenog time što ima angiogenezu, invaziju ili metastazu.
4. Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1 za uporabu u liječenju tumora ili raka naznačenog time što ima angiogenezu, invaziju ili metastazu.
5. Spoj za uporabu prema zahtjevu 3 ili 4, naznačen time što je rak, rak glave i vrata, rak dojke, rak jednjaka, rak maternice, rak jajnika, kolorektalni rak, rak endometrija, rak želuca, rak tankog crijeva, rak mokraćnog mjehura ili sarkom.
6. Spoj za uporabu prema zahtjevu 5, naznačen time što je rak:
(a) rak glave i vrata, poželjno pri čemu je rak karcinom pločastih stanica glave i vrata (SCCHN) ili adenoidni cistični karcinom; ili
(b) rak dojke, poželjno pri čemu je rak dojke (i) HER2-pozitivan rak dojke, ili (ii) HER2-negativan rak dojke, ili (iii) trostruko negativan rak dojke; ili
(c) kolorektalni karcinom; ili
(d) rak jednjaka, poželjno pri čemu je rak jednjaka adenokarcinom jednjaka; ili
(e) rak maternice; ili
(f) rak jajnika; ili
(g) sarkom, poželjno pri čemu je sarkom, sarkom maternice, fibrosarkom, sinovijalni sarkom, sarkom mekog tkiva ili angiosarkom; ili
(h) rak želuca; ili
(i) rak tankog crijeva, poželjno pri čemu je rak tankog crijeva adenokarcinom tankog crijeva; ili
(j) rak mokraćnog mjehura; ili
(k) urotelni karcinom.
7. Spoj za uporabu prema bilo kojem od zahtjeva 4-6, za uporabu u kombinaciji s protutijelom proteina programirane smrti (PD-1).
8. Spoj za uporabu prema bilo kojem od zahtjeva 4-6, za uporabu u kombinaciji s protutijelom L1 proteina programirane smrti (PD-L1).
9. Spoj za uporabu prema bilo kojem od zahtjeva 4-6, za uporabu u kombinaciji s anti-EGFR (receptor epidermalnog faktora rasta) protutijelom, poželjno pri čemu je anti-EGFR protutijelo anti-EGFR mAb, i/ili rak je rak glave i vrata, poželjno pri čemu je rak karcinom pločastih stanica glave i vrata (SCCHN), i/ili anti-EGFR mAb je cetuksimab.
10. Spoj za uporabu prema bilo kojem od zahtjeva 4-6, za uporabu u kombinaciji s HER2 protutijelom (receptor humanog epidermalnog faktora rasta), poželjno pri čemu je HER2 protutijelo HER2 mAb, i/ili rak je rak dojke, i/ili HER2 mAb je trastuzumab.
11. Spoj za uporabu prema bilo kojem od zahtjeva 4-10 kod subjekta, pri čemu je spoj ili njegova farmaceutski prihvatljiva sol u farmaceutski prihvatljivom nosaču.
12. Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol za uporabu prema zahtjevu 6, naznačen time što je rak HER2-negativan rak dojke ili karcinom pločastih stanica glave i vrata (SCCHN) kod subjekta.
13. Spoj za uporabu prema bilo kojem od zahtjeva 5-10 i 12 naznačen time što je za uporabu u kombinaciji s terapijom zračenjem.
14. Spoj za uporabu prema bilo kojem od zahtjeva 5-10 i 12-13 naznačen time što je za uporabu u kombinaciji s kirurškim zahvatom.
15. Spoj za uporabu prema bilo kojem od zahtjeva 5-10 i 12-14, naznačen time što je subjekt čovjek.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482030P | 2017-04-05 | 2017-04-05 | |
| US201762526677P | 2017-06-29 | 2017-06-29 | |
| US201762586416P | 2017-11-15 | 2017-11-15 | |
| US15/814,105 US9938288B1 (en) | 2017-04-05 | 2017-11-15 | Macrocyclic compound and uses thereof |
| EP18719390.9A EP3606928B1 (en) | 2017-04-05 | 2018-04-03 | Macrocyclic compound and uses thereof |
| PCT/US2018/025887 WO2018187331A1 (en) | 2017-04-05 | 2018-04-03 | Macrocyclic compound and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221385T1 true HRP20221385T1 (hr) | 2023-01-06 |
Family
ID=63104288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221385TT HRP20221385T1 (hr) | 2017-04-05 | 2018-04-03 | Makrociklički spoj i njegova uporaba |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11725015B2 (hr) |
| EP (2) | EP4119563A3 (hr) |
| JP (4) | JP6366873B1 (hr) |
| KR (2) | KR102634732B1 (hr) |
| CN (2) | CN115093429A (hr) |
| AU (2) | AU2018250147B2 (hr) |
| BR (1) | BR112019020208A2 (hr) |
| CA (1) | CA3056945A1 (hr) |
| CL (1) | CL2019002854A1 (hr) |
| CO (1) | CO2019011538A2 (hr) |
| DK (1) | DK3606928T3 (hr) |
| EC (1) | ECSP19075677A (hr) |
| ES (1) | ES2931533T3 (hr) |
| HR (1) | HRP20221385T1 (hr) |
| HU (1) | HUE060466T2 (hr) |
| IL (2) | IL288991B2 (hr) |
| JO (1) | JOP20190234B1 (hr) |
| LT (1) | LT3606928T (hr) |
| MA (1) | MA48027B1 (hr) |
| MD (1) | MD3606928T2 (hr) |
| MX (1) | MX2019011982A (hr) |
| PE (1) | PE20200602A1 (hr) |
| PH (1) | PH12019502197A1 (hr) |
| PL (1) | PL3606928T3 (hr) |
| PT (1) | PT3606928T (hr) |
| RS (1) | RS63755B1 (hr) |
| SA (1) | SA519410259B1 (hr) |
| SG (1) | SG11201908603PA (hr) |
| SI (1) | SI3606928T1 (hr) |
| TW (1) | TWI781163B (hr) |
| UA (1) | UA124399C2 (hr) |
| WO (1) | WO2018187331A1 (hr) |
| ZA (1) | ZA201906279B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3160970A4 (en) | 2014-06-30 | 2017-12-27 | President and Fellows of Harvard College | Synthesis of halichondrin analogs and uses thereof |
| WO2016176560A1 (en) | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| KR102634732B1 (ko) | 2017-04-05 | 2024-02-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 마크로시클릭 화합물 및 그의 용도 |
| US9938288B1 (en) | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| BR112020000141A2 (pt) * | 2017-07-06 | 2020-07-14 | President And Fellows Of Harvard College | síntese de halicondrinas |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| US11407762B2 (en) | 2017-11-15 | 2022-08-09 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK187280A (da) | 1980-04-30 | 1981-10-31 | Novo Industri As | Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode |
| US5436238A (en) | 1992-03-12 | 1995-07-25 | President And Fellows Of Harvard College | Halichondrins and related compounds |
| US5338865A (en) | 1992-03-12 | 1994-08-16 | President And Fellows Of Harvard College | Synthesis of halichondrin B and norhalichondrin B |
| GB9206244D0 (en) | 1992-03-23 | 1992-05-06 | Pharma Mar Sa | Cytotoxic compound from a marine sponge |
| DE4229425A1 (de) | 1992-09-03 | 1994-03-10 | Kodak Ag | Vorrichtung zum stapelweisen Ablegen und Ausrichten von einzeln zugeführten Blättern |
| US5426194A (en) * | 1993-01-19 | 1995-06-20 | Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 1 |
| US5352804A (en) * | 1993-01-19 | 1994-10-04 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Isolation and structure of Halistatin 2 |
| JP2818381B2 (ja) | 1994-01-18 | 1998-10-30 | 帝人株式会社 | ７−チアプロスタグランジン類およびその製造法 |
| US6653341B1 (en) | 1998-06-17 | 2003-11-25 | Eisai Co., Ltd. | Methods and compositions for use in treating cancer |
| US8097648B2 (en) * | 1998-06-17 | 2012-01-17 | Eisai R&D Management Co., Ltd. | Methods and compositions for use in treating cancer |
| BRPI9911326B8 (pt) | 1998-06-17 | 2021-05-25 | Eisai Co Ltd | análogos macrocíclicos e métodos para seu uso e preparação |
| JP2001305734A (ja) | 2000-04-20 | 2001-11-02 | Fuji Photo Film Co Ltd | 光重合性組成物 |
| JP2003261447A (ja) | 2002-03-07 | 2003-09-16 | Kyosei Seiyaku Kk | 抗腫瘍剤 |
| EP2522663B1 (en) | 2004-06-03 | 2015-04-01 | Eisai R&D Management Co., Ltd. | Intermediates for the preparation of halichondrin B |
| WO2006076100A2 (en) | 2004-12-09 | 2006-07-20 | Eisai Co. Ltd. | Tubulin isotype screening in cancer therapy using halichondrin b analogs |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| AU2008226986B2 (en) | 2007-03-07 | 2011-04-07 | Interdigital Technology Corporation | Method and apparatus for generating and processing a MAC-ehs protocol data unit |
| JP2010530437A (ja) | 2007-06-18 | 2010-09-09 | メディミューン，エルエルシー | ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療 |
| US8093410B2 (en) | 2007-10-03 | 2012-01-10 | Eisai R&D Management Co., Ltd. | Intermediates and methods for the synthesis of halichondrin B analogs |
| RU2010118063A (ru) | 2007-11-16 | 2011-12-27 | ЭЙСАЙ Ар энд Ди МЕНЕДЖМЕНТ КО., ЛТД. (JP) | Новое промежуточное соединение для синтеза аналога галихондрина в и новая реакция десульфонилирования, применяемая для получения промежуточного соединения |
| JP6001857B2 (ja) | 2008-04-04 | 2016-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンｂ類似体 |
| CN102803254B (zh) | 2010-01-26 | 2016-09-14 | 卫材R&D管理有限公司 | 用于软海绵素b类似物合成的呋喃并[3,2-b]吡喃衍生物 |
| WO2012096926A2 (en) | 2011-01-10 | 2012-07-19 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
| WO2012147900A1 (en) | 2011-04-28 | 2012-11-01 | Eisai R&D Management Co., Ltd. | Microreactor process for halichondrin b analog synthesis |
| CN104024237B (zh) | 2011-12-16 | 2016-02-24 | 阿方拉研究股份有限公司 | 用于制备3-((2s,5s)-4-亚甲基-5-(3-氧代丙基)四氢呋喃-2-基)丙醇衍生物的方法及其有用的中间体 |
| CA2860446C (en) | 2011-12-29 | 2017-01-10 | Alphora Research Inc. | 2-((2s,3s,4r,5r)-5-((s)-3-amino-2-hydroxyprop-1-yl)-4-methoxy-3-(phenylsulfonylmethyl)tetrahydrofuran-2-yl)acetaldehyde derivatives and process for their preparation |
| EP2831082B1 (en) | 2012-03-30 | 2019-02-20 | Sandoz AG | Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein |
| KR20150003156A (ko) * | 2012-11-30 | 2015-01-08 | 항조우 질록스 파마 컴퍼니 리니티드 | 라파마이신 유사체 및 이의 제조 방법 |
| AR096238A1 (es) | 2013-05-15 | 2015-12-16 | Alphora Res Inc | Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo |
| AU2014286880B2 (en) | 2013-07-03 | 2017-12-14 | Sandoz Ag | Synthetic process for preparation of macrocyclic C1-keto analogs of Halichondrin B and intermediates useful therein including intermediates containing -SO2-(p-TOLYL) groups |
| CN114716453A (zh) * | 2013-11-04 | 2022-07-08 | 卫材R&D管理有限公司 | 软海绵素b的类似物合成中有用的大环化反应和中间体 |
| EP3077399B1 (en) | 2013-12-06 | 2019-02-20 | Eisai R&D Management Co., Ltd. | Methods useful in the synthesis of halichondrin b analogs |
| EP3160970A4 (en) * | 2014-06-30 | 2017-12-27 | President and Fellows of Harvard College | Synthesis of halichondrin analogs and uses thereof |
| WO2016038624A1 (en) | 2014-09-09 | 2016-03-17 | Cipla Limited | "process for the preparation of macrocyclic ketone analogs of halichondrin b or pharmaceutically acceptable salts and intermediates thereof" |
| WO2016176560A1 (en) * | 2015-04-30 | 2016-11-03 | President And Fellows Of Harvard College | Chromium-mediated coupling and application to the synthesis of halichondrins |
| JP6840090B2 (ja) | 2015-05-07 | 2021-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ハリコンドリンマクロライドの合成に有用な大環状化反応および中間体および他のフラグメント |
| LT3423105T (lt) | 2016-03-02 | 2021-09-10 | Eisai R&D Management Co., Ltd. | Antikūno-vaisto konjugatai eribulino pagrindu ir jų panaudojimo būdai |
| JP6978758B2 (ja) | 2016-11-11 | 2021-12-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | パラジウム媒介ケトール化 |
| US20210187059A1 (en) | 2017-02-20 | 2021-06-24 | Polyphor Ag | Pharmaceutical combinations for treating cancer |
| KR102634732B1 (ko) | 2017-04-05 | 2024-02-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 마크로시클릭 화합물 및 그의 용도 |
| US9938288B1 (en) * | 2017-04-05 | 2018-04-10 | President And Fellows Of Harvard College | Macrocyclic compound and uses thereof |
| US11498892B2 (en) | 2017-07-06 | 2022-11-15 | President And Fellows Of Harvard College | Fe/Cu-mediated ketone synthesis |
| WO2019009956A1 (en) | 2017-07-06 | 2019-01-10 | President And Fellows Of Harvard College | SUMMARY OF MEDIUM MEDIATED KETONE |
| BR112020000141A2 (pt) | 2017-07-06 | 2020-07-14 | President And Fellows Of Harvard College | síntese de halicondrinas |
| US11407762B2 (en) | 2017-11-15 | 2022-08-09 | President And Fellows Of Harvard College | Macrocyclic compounds and uses thereof |
-
2018
- 2018-04-03 KR KR1020197032300A patent/KR102634732B1/ko active IP Right Grant
- 2018-04-03 MD MDE20200167T patent/MD3606928T2/ro unknown
- 2018-04-03 BR BR112019020208A patent/BR112019020208A2/pt unknown
- 2018-04-03 UA UAA201910898A patent/UA124399C2/uk unknown
- 2018-04-03 EP EP22187494.4A patent/EP4119563A3/en active Pending
- 2018-04-03 CA CA3056945A patent/CA3056945A1/en active Pending
- 2018-04-03 CN CN202210696425.5A patent/CN115093429A/zh active Pending
- 2018-04-03 EP EP18719390.9A patent/EP3606928B1/en active Active
- 2018-04-03 PT PT187193909T patent/PT3606928T/pt unknown
- 2018-04-03 ES ES18719390T patent/ES2931533T3/es active Active
- 2018-04-03 HU HUE18719390A patent/HUE060466T2/hu unknown
- 2018-04-03 JP JP2018071700A patent/JP6366873B1/ja active Active
- 2018-04-03 AU AU2018250147A patent/AU2018250147B2/en active Active
- 2018-04-03 IL IL288991A patent/IL288991B2/en unknown
- 2018-04-03 HR HRP20221385TT patent/HRP20221385T1/hr unknown
- 2018-04-03 JO JOP/2019/0234A patent/JOP20190234B1/ar active
- 2018-04-03 SI SI201830813T patent/SI3606928T1/sl unknown
- 2018-04-03 TW TW107111975A patent/TWI781163B/zh active
- 2018-04-03 JP JP2019555001A patent/JP7168580B2/ja active Active
- 2018-04-03 DK DK18719390.9T patent/DK3606928T3/da active
- 2018-04-03 CN CN201880033165.5A patent/CN110831946B/zh active Active
- 2018-04-03 KR KR1020247003838A patent/KR20240023674A/ko active Application Filing
- 2018-04-03 MX MX2019011982A patent/MX2019011982A/es unknown
- 2018-04-03 PE PE2019001975A patent/PE20200602A1/es unknown
- 2018-04-03 WO PCT/US2018/025887 patent/WO2018187331A1/en active Application Filing
- 2018-04-03 RS RS20221078A patent/RS63755B1/sr unknown
- 2018-04-03 SG SG11201908603P patent/SG11201908603PA/en unknown
- 2018-04-03 MA MA48027A patent/MA48027B1/fr unknown
- 2018-04-03 LT LTEPPCT/US2018/025887T patent/LT3606928T/lt unknown
- 2018-04-03 PL PL18719390.9T patent/PL3606928T3/pl unknown
-
2019
- 2019-09-23 ZA ZA2019/06279A patent/ZA201906279B/en unknown
- 2019-09-24 PH PH12019502197A patent/PH12019502197A1/en unknown
- 2019-10-03 IL IL269788A patent/IL269788B/en unknown
- 2019-10-04 CL CL2019002854A patent/CL2019002854A1/es unknown
- 2019-10-06 SA SA519410259A patent/SA519410259B1/ar unknown
- 2019-10-17 CO CONC2019/0011538A patent/CO2019011538A2/es unknown
- 2019-10-23 EC ECSENADI201975677A patent/ECSP19075677A/es unknown
-
2021
- 2021-02-04 US US17/167,480 patent/US11725015B2/en active Active
-
2022
- 2022-06-30 JP JP2022106421A patent/JP7400025B2/ja active Active
- 2022-12-20 AU AU2022291454A patent/AU2022291454B2/en active Active
-
2023
- 2023-06-21 US US18/339,227 patent/US20230406863A1/en active Pending
- 2023-12-06 JP JP2023206236A patent/JP2024028872A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221385T1 (hr) | Makrociklički spoj i njegova uporaba | |
| HRP20160697T1 (hr) | Duokarmicin adcs koji pokazuje poboljšanu antitumorsku aktivnost in vivo | |
| HRP20210977T1 (hr) | Ciljano inhibiranje tgf beta | |
| JP2022000445A (ja) | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 | |
| HRP20211129T1 (hr) | Nukleinske kiseline koje kodiraju humana antitijela na sialyl-lewis a | |
| Kasper et al. | Targeted therapies in gastroesophageal cancer | |
| JP2017533912A5 (hr) | ||
| RU2016150650A (ru) | Комбинированная терапия для лечения рака | |
| Le Bras et al. | Esophageal cancer: the latest on chemoprevention and state of the art therapies | |
| Efferth | Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib | |
| JP2014065748A5 (ja) | 癌治療剤 | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| Ayub et al. | Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line | |
| Palayekar et al. | The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer | |
| EP4008338A4 (en) | USE OF FGF21 IN THE PREPARATION OF A MEDICINE FOR TREATING COLORECTAL CANCER | |
| RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
| MX2013015333A (es) | Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos. | |
| Norguet et al. | Targetting esophageal and gastric cancers with monoclonal antibodies | |
| RU2017105817A (ru) | Комбинированная терапия | |
| Cellini et al. | Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma | |
| Chilà et al. | Multi-chemotherapeutic schedules containing the pan-FGFR inhibitor ARQ 087 are safe and show antitumor activity in different xenograft models | |
| JP2011500723A5 (hr) | ||
| Pohl et al. | Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo | |
| RU2017120388A (ru) | Прогнозирование ответа на антагонист vegf | |
| Lam et al. | Target therapy for esophageal adenocarcinoma |